We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-0.32%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$147M
AUM Growth
-$58.2M
Cap. Flow
-$51.6M
Cap. Flow %
-35.04%
Top 10 Hldgs %
96.04%
Holding
15
New
2
Increased
5
Reduced
4
Closed
2
Avg Time Held
0.8 quarters
Top 10 Avg Time Held
0.9 quarters
Top 20 Avg Time Held
0.8 quarters

Top Buys

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$11.2M
2
DVAX icon
Dynavax Technologies
DVAX
+$5.64M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$2.58M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.21M
5
AKAO
Achaogen Inc
AKAO
+$1.45M

Top Sells

Rank Stock Value
1
CMRX icon
Chimerix, Inc.
CMRX
+$32.4M
2
RLYP
RELYPSA INC COM
RLYP
+$29.6M
3
LITS icon
Lite Strategy Inc
LITS
+$6.84M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$5.03M
5
CALA
Calithera Biosciences, Inc
CALA
+$1.22M

Sector Composition

Rank Sector Weight
1 Healthcare 78.31%
2 Miscellaneous 21.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARAV
1
DELISTED
Aravive, Inc. Common Stock
ARAV
$37.5M 25.43%
339,871
-42,874
-11% -$5.03M
2014 Q4
1 quarter
RLYP
2
DELISTED
RELYPSA INC COM
RLYP
$29.6M 20.08%
819,833
-819,832
-50% -$29.6M
2014 Q4
1 quarter
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$19.4M 13.17%
1,377,497
– –
2014 Q4
1 quarter
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$18.3M 12.41%
633,293
+409,740
+183% +$11.2M
2014 Q4
1 quarter
CMRX icon
5
DELISTED
Chimerix, Inc.
CMRX
$9.48M 6.44%
251,608
-816,692
-76% -$32.4M
2014 Q4
1 quarter
DVAX icon
6
DELISTED
Dynavax Technologies
DVAX
$9.13M 6.2%
406,993
+294,293
+261% +$5.64M
2014 Q4
1 quarter
CALA
7
DELISTED
Calithera Biosciences, Inc
CALA
$5.22M 3.55%
27,802
-3,437
-11% -$1.22M
2014 Q4
1 quarter
MRNS icon
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.71M 3.2%
131,063
+26,216
+25% +$1.15M
2014 Q4
1 quarter
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$3.41B
$4.34M 2.94%
133,061
+64,300
+94% +$2.21M
2014 Q4
1 quarter
KPTI icon
10
Karyopharm Therapeutics
KPTI
$13.7M
$3.88M 2.63%
8,446
– –
2014 Q4
1 quarter
GEVA
11
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$2.38M 1.61%
+24,379
New +$2.58M
2015 Q1
0 quarters
SAGE icon
12
DELISTED
Sage Therapeutics
SAGE
$2.2M 1.49%
43,770
+8,400
+24% +$361K
2014 Q4
1 quarter
AKAO
13
DELISTED
Achaogen Inc
AKAO
$1.26M 0.85%
+128,728
New +$1.45M
2015 Q1
0 quarters
LITS icon
14
Lite Strategy Inc
LITS
$38.6M
– –
-80,070
Closed -$6.84M –
ALIM icon
15
DELISTED
Alimera Sciences
ALIM
– –
-13,979
Closed -$1.16M –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q1 2015 Portfolio in Review

As of Q1 2015, New Leaf Venture Partners held 15 positions worth $147M, down 28% from $206M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

New Leaf Venture Partners withdrew a net $51.6M in Q1 2015, closing 2 positions and reducing 4 holdings. Its most notable exit was Lite Strategy Inc, an estimated $6.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 75% a quarter earlier, followed by Miscellaneous.

Against the trend, New Leaf Venture Partners opened a new position in SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $2.38M.

  • New Leaf Venture Partners's largest Q1 2015 buy was SYNAGEVA BIOPHARMA CORP COM STK (DE): 24,379 shares worth $2.38M.
  • New Leaf Venture Partners added most to Alder Biopharmaceuticals in Q1 2015, an estimated $11.2M increase.
  • New Leaf Venture Partners's biggest Q1 2015 reduction was Chimerix, Inc., cutting an estimated $32.4M.
  • New Leaf Venture Partners fully exited Lite Strategy Inc in Q1 2015, selling an estimated $6.84M.
  • New Leaf Venture Partners's ten largest holdings make up 96% of its $147M portfolio in Q1 2015.
  • New Leaf Venture Partners opened 2 new positions and closed 2 in Q1 2015.
  • New Leaf Venture Partners's portfolio value fell 28% quarter-over-quarter to $147M.

Based on New Leaf Venture Partners's 13F filing for Q1 2015, filed 15 May 2015.